- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02994732
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers
March 14, 2019 updated by: BioMed Valley Discoveries, Inc
A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BVD-523 Following Single Oral Dose Administration in Healthy Male Subjects
The primary objective of this study is to characterize the metabolic disposition, pharmacokinetics (PK), and routes of elimination of [14C]-labeled BVD-523 after administration of a single, oral dose to healthy male subjects.
The secondary objective of this study is to evaluate the safety and tolerability of a single oral dose of [14C]-labeled BVD-523 in healthy male subjects.
Study Overview
Detailed Description
This study will be an open-label, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males, between 18 and 65 years of age, inclusive, at Screening
- Have a body mass index range of 18.5 to 32.0 kg/m2, inclusive, at Screening
- In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs measurements at Screening or Check-in and PE findings at Check-in as determined by the Investigator (or designee)
- Clinical laboratory evaluations (including clinical chemistry panel [fasted at least 8 hours], hematology/complete blood count [CBC], and urinalysis [UA] within the reference range for the test laboratory at Screening and Check-in, unless deemed not clinically significant by the Investigator (or designee)
- Negative test for selected drugs of abuse and cotinine at Screening (does not include alcohol) and at Check-in (does include alcohol)
- Negative hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) and negative human immunodeficiency virus (HIV) antibody screens at Screening
- Males will be surgically sterile for at least 90 days (confirmed by documented azoospermia) or, when sexually-active with female partners of child-bearing potential, will agree to use contraception as detailed in Section 6.3.3 from Check-in until 90 days following Discharge
- Males must be willing to refrain from sperm donation from Check-in to 90 days from day of dosing
- Able to comprehend and willing to sign an ICF
- A minimum of 1 bowel movement per day.
Exclusion Criteria:
- Significant history or clinical manifestation of any metabolic, allergic, infectious, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator [or designee]) prior to Check-in
- History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) prior to Check-in
- History of stomach or intestinal surgery or resection that could alter absorption or excretion of orally administered drugs prior to Check-in except appendectomy, and hernia repair will be allowed if it was not associated with;
- History of Gilbert's Syndrome
- History or presence of an abnormal ECG that, in the Investigator's (or designee's) opinion, is clinically significant
- History of alcoholism or drug addiction within 1 year prior to Check-in
- History of nicotine use within 6 months prior to Check-in or positive cotinine at Screening or Check-in
- Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in. The previous radiolabeled study drug must have been received more than 6 months prior to Check-in for this study and the total exposure from this study and the previous study will be within the recommended levels considered safe, per United States (US) Title 21 Code of Federal Regulations (CFR) 361.1 (eg, less than 3,000 mrem whole body annual exposure)
- Exposure to significant radiation (eg, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to Check-in
- Use of any drugs or substances known to be strong inhibitors or strong inducers of CYP3A enzyme within 30 days prior to study drug administration, unless otherwise stated, and throughout the study
- Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives (if known) or 30 days prior to Check-in, whichever is longer
- Use of any prescription medications/products within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee)
- Use of any over-the-counter, nonprescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee)
- Poor peripheral venous access prior to Check-in
- Donation of whole blood from 56 days prior to Screening through Discharge, inclusive, or of plasma from 30 days prior to Screening through Discharge, inclusive
- Receipt of blood products within 2 months prior to Check-in
- Any acute or chronic condition that, in the opinion of the Investigator (or designee), would limit the subject's ability to complete or participate in this clinical study
- Any other unspecified reason that, in the opinion of the Investigator (or designee) or Sponsor, make the subject unsuitable for enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]-BVD-523 600mg single dose
Open-label, nonrandomized, absorption, metabolism, and excretion study of [14C]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).
|
[14C]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) Tmax
Time Frame: Collected over 5 days
|
Time to peak concentration (Tmax), PK blood samples were taken at the following time points 0 (predose), 30 min, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post dose.
|
Collected over 5 days
|
Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) Cmax
Time Frame: Collected over 5 days
|
peak (maximum) concentration
|
Collected over 5 days
|
Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) t1/2
Time Frame: Collected over 15 days
|
Elimination half-life
|
Collected over 15 days
|
Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) AUC
Time Frame: Collected over 15 dyas
|
Area under Curve (AUC), 0-24 hr
|
Collected over 15 dyas
|
Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) CL/F
Time Frame: Collected over 15 days
|
Oral Clearance (CL/F)
|
Collected over 15 days
|
Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) V/F
Time Frame: Collected over 15 days
|
Apparent volume of distribution (V/F)
|
Collected over 15 days
|
Excretion Rate of 14C-labeled BVD-523(Radioactivity in Feces)
Time Frame: Collected over 15 days
|
Percent of dose excreted in feces
|
Collected over 15 days
|
Excretion Rate of 14C-labeled BVD-523(Radioactivity in Urine)
Time Frame: Collected over 15 days
|
Percent of dose excreted in urine
|
Collected over 15 days
|
Cumulative Whole Blood: Plasma Ratio Calculated for AUC0-12
Time Frame: Collected in 12 hrs
|
AUC from time zero to the 12 hr time point with concentration above the lower limit of quantitation
|
Collected in 12 hrs
|
Cumulative Whole Blood: Plasma Ratio Calculated for AUC 0-24
Time Frame: Collected in 24 hrs
|
AUC from time zero to 24 hrs
|
Collected in 24 hrs
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-related Adverse Events
Time Frame: 27 days
|
Any treatment-emergent adverse events related or likely related to study treatment
|
27 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2017
Primary Completion (Actual)
February 1, 2017
Study Completion (Actual)
May 15, 2017
Study Registration Dates
First Submitted
November 14, 2016
First Submitted That Met QC Criteria
December 13, 2016
First Posted (Estimate)
December 16, 2016
Study Record Updates
Last Update Posted (Actual)
June 17, 2019
Last Update Submitted That Met QC Criteria
March 14, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- 523HV001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on [14C]-BVD-523
-
BioMed Valley Discoveries, IncTerminatedAdvanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene AlterationUnited States
-
HutchmedActive, not recruitingImumune Thrombocytopenia(ITP) Human Mass BalanceChina
-
BioMed Valley Discoveries, IncCompletedAdvanced Solid TumorsUnited States
-
BioMed Valley Discoveries, IncCompletedMyelodysplastic Syndrome | Acute Myelogenous LeukemiaUnited States
-
Dana-Farber Cancer InstituteBioMed Valley Discoveries, IncActive, not recruiting
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditionsUnited States, Puerto Rico
-
UNC Lineberger Comprehensive Cancer CenterPfizer; BioMed Valley Discoveries, IncRecruitingMelanoma | Pancreatic Cancer | Tumor, SolidUnited States
-
University of UtahBioMed Valley Discoveries, IncCompletedGastrointestinal NeoplasmsUnited States
-
M.D. Anderson Cancer CenterEli Lilly and Company; BioMed Valley Discoveries, IncRecruiting